Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 9, Pages 1083-1089
Publisher
Informa UK Limited
Online
2017-07-25
DOI
10.1080/13543784.2017.1360274
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
- (2016) Vasilios G. Athyros et al. Current Vascular Pharmacology
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
- (2016) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- New fixed dose chemical combinations: the way forward for better diabetes type II management?
- (2016) Suhaj Abdulsalim et al. EXPERT OPINION ON PHARMACOTHERAPY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Combination therapy for type 2 diabetes: dapagliflozin plus metformin
- (2015) Xueying Tan et al. EXPERT OPINION ON PHARMACOTHERAPY
- Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel
- (2015) Christoph Kapitza et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of glucagon-like peptide-1 agents on left ventricular function: Systematic review and meta-analysis
- (2014) Rui Liu et al. ANNALS OF MEDICINE
- The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates
- (2014) C. F. Gotfredsen et al. DIABETES
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
- (2014) Eva W Iepsen et al. EXPERT OPINION ON PHARMACOTHERAPY
- A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
- (2012) Eduard Montanya EXPERT OPINION ON PHARMACOTHERAPY
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Glycemic Management of Type 2 Diabetes Mellitus
- (2012) Faramarz Ismail-Beigi NEW ENGLAND JOURNAL OF MEDICINE
- Management of type 2 diabetes: new and future developments in treatment
- (2011) Abd A Tahrani et al. LANCET
- Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications
- (2010) S. Lesven et al. ANNALES D ENDOCRINOLOGIE
- The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
- (2009) Kevin M. Pantalone et al. ACTA DIABETOLOGICA
- Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects
- (2009) R E Steinert et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The effects of glucagon-like peptide-1 on the beta cell
- (2009) T. Vilsbøll DIABETES OBESITY & METABOLISM
- Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
- (2009) Kausik K Ray et al. LANCET
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now